shutterstock_1460679143_peter_porrini
Peter Porrini / Shutterstock.com
9 February 2021AmericasAlex Baldwin

Federal Circuit denies further term extensions to shoulder surgery patentee

The US Court of Appeals for the Federal Circuit has upheld a decision by a district court that an inventor cannot further extend his shoulder surgery patent after already being granted a term adjustment period by the US Patent and Trademark Office (USPTO).

The US  District Court for the Eastern District of Virginia affirmed a USPTO decision of March 25 last year to deny an additional 655-day patent term adjustment on the grounds that Steven Chudik was not entitled to a “C-delay”—a delay period where the USPTO fails to issue a patent after three years from the filing date.

C-delay provisions cover a delay due to an appellate review of the patent by the Patent Trial and Appeal Board (PTAB) or Federal court.

The decision was contested by Chudik and appealed to the Federal Circuit, which upheld the USPTO’s decision and district court’s affirmation in a ruling handed down on February 8.

The USPTO concluded that the determining factors of a C-delay did not apply here due to the PTAB’s jurisdiction over the appeals “never attached” and because there was no board or reviewing court reversal.

“Our conclusion requires affirmance of the district court’s upholding of the USPTO’s denial to Dr Chudik of the requested C-delay. We do not address the USPTO’s other ground for its denial—concerning when jurisdiction over an appeal to the board attaches. But we add one point relevant to some scenarios involving examiners reopening prosecution after a notice of appeal has been filed,” the Federal Circuit concluded.

Decade-long dispute

Chudik fought an 11-year legal battle to renew his ‘guide for shoulder surgery’ patent (US Patent number 9,968,459).

Following four separate appeals and delays from 2006 to 2018, the USPTO extended the term of the patent by 1,967 days.

Chudik filed a petition with the USPTO arguing that 754 days should be added to the patent term to account for the time that his four appeals had been pending before the board. The PTO rejected this, but granted him an additional 132 days on unrelated grounds, resulting in a total of 2,099 days.

After Chudik asked twice for the USPTO to reconsider its decision, the USPTO made a final adjustment, reducing the 2,099 days to 2,066.

Chudik then filed a complaint against the USPTO’s director with the Virginia court, alleging he was entitled to 655 additional days—the C-delay—on the grounds of appellate review.

The district court rejected Chudik’s challenge.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Americas
2 March 2017   The US Court of Appeals for the Federal Circuit has partially affirmed a ruling by a district court in a patent dispute between Bayer and Dow Agrosciences.
Americas
6 February 2018   Yesterday, the US Court of Appeals for the Federal Circuit backed a lower court’s decision to dismiss a declaratory judgment lawsuit filed by AbbVie over its drug Humira.
Americas
22 April 2021   In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.

More on this story

Americas
2 March 2017   The US Court of Appeals for the Federal Circuit has partially affirmed a ruling by a district court in a patent dispute between Bayer and Dow Agrosciences.
Americas
6 February 2018   Yesterday, the US Court of Appeals for the Federal Circuit backed a lower court’s decision to dismiss a declaratory judgment lawsuit filed by AbbVie over its drug Humira.
Americas
22 April 2021   In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.